| Authors: |
Ariaee A; Translational Nanomedicines and Biotherapeutics, University of South Australia, Adelaide, SA 5000, Australia; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia., Noueihad K; Translational Nanomedicines and Biotherapeutics, University of South Australia, Adelaide, SA 5000, Australia; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia., Hunter A; Translational Nanomedicines and Biotherapeutics, University of South Australia, Adelaide, SA 5000, Australia; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia., Wignall A; Translational Nanomedicines and Biotherapeutics, University of South Australia, Adelaide, SA 5000, Australia; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia., Wardill HR; Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia; Supportive Oncology Research Group, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia., Davies M; Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia; Supportive Oncology Research Group, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia., Prestidge CA; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia., Joyce P; Translational Nanomedicines and Biotherapeutics, University of South Australia, Adelaide, SA 5000, Australia; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia. Electronic address: paul.joyce@unisa.edu.au. |
